The research on genetic susceptibility of inflammatory bowel diseases (IBD) has been tremendous and over 10 chromosomal regions have been identified by genome-wide scanning. Further fine mapping as well as candidate gene studies have already led to the identification of a number of susceptibility genes including CARD15, DLG5, OCTN1 and 2, NOD1, HLA, and TLR4. The CARD15 gene is undoubtedly replicated most widely and most understood at present. CARD15 is involved in the recognition of bacterial peptidoglycan-derived muramyl dipeptide (MDP) and will stimulate secretion of antimicrobial peptides including alpha-defensins (also called cryptdins) to protect the host from invasion. Genetic research in IBD has advanced our understanding of the clinical heterogeneity of the disease and has started to tackle the complex interactions between genetic risk factors and environmental risk factors in IBD. Genes also interfere with the metabolization of drugs and may influence the clinical response and the drug-related toxicity. Interesting pharmacogenetic data with respect to steroids, azathioprine, and infliximab have been generated in IBD. Overall, it is anticipated that genetic markers in the future will be implemented in an integrated molecular diagnostic and prognostic approach of our patients. Genes and Immunity (2005) 6, 637-645.
Introduction
The inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC) are chronic relapsing inflammatory diseases of the gastrointestinal tract. The precise aetiology of the disease is unknown, but an interplay of environmental risk factors and immunologic changes will trigger the onset of the disease in a genetically susceptible host. Epidemiological studies in the past suggested a genetic susceptibility that has been confirmed by molecular data from total genome scans and from candidate gene studies. Since the start of genetics research in IBD 10 years ago, important progress has been made and a number of susceptibility genes have been identified. These have further advanced researchers in unravelling the pathophysiology of IBD. In this respect, the identification of the caspase-recruitment domain (CARD)15 gene has underscored the importance of the bacterial flora and has focused attention on the role of pattern recognition receptors (PRRs) and other pathways of the innate immune system. The clinical impact of the genetic findings so far is situated in understanding the heterogeneity of IBD in terms of location, age at onset and behaviour, and also in predicting answer to and side effects of particular treatments.
Genetic epidemiology
Several lines of evidence suggest a genetic contribution to the pathogenesis of IBD. First, there are considerable differences in the prevalence of IBD among ethnic groups. 1, 2 The highest prevalence is seen among Caucasians. Afro-American and Asian individuals carry a much lower risk, although the incidence of IBD is rising even in these ethnic groups. The prevalence in the Jewish population is two to four times higher than any other ethnic group and is independent from geographic location and the period of analysis. The highest risk is seen among Ashkenazi Jews, in comparison with Sephardic Oriental Jews.
Family studies have reported an important familial association of the disease. [3] [4] [5] Around 5.5-22.5% of patients with IBD report having another family member also affected with IBD. In fact, the most important risk factor for IBD is having a family member with the disease. The relative risk for a sibling of a CD patient to also become affected is 13-36, and for a sibling of a UC patient this risk is 7-17. The greatest risk appears for children of whom both parents have IBD (430% at the age of 28 years). 6 Patients with IBD and a familial history tend to get their disease at an earlier age than patients without a familial history and show an increased concordance in disease type (CD or UC) and probably also disease location. The severity of the disease, in contrast, does not differ between familial or sporadic disease.
Twin studies provide solid evidence for the contribution of genetic and/or environmental factors. [7] [8] [9] [10] The fact that monozygotic twins with CD have a much higher disease concordance (37%) than dizygotic twins (7%) indicates that genetic factors play an important role. For UC, the concordance rates are less (10 vs 3% for monozygotic and dizygotic twins, respectively), suggesting a less important genetic impact, in comparison with CD.
A number of subclinical markers have been identified in unaffected family members of IBD patients. These markers might indicate who is at risk of developing the disease or in whom early disease is already present. The markers studied most are intestinal permeability, and a number of anti-microbial antibodies: anti-Saccharomyces cerevisiae antibodies (ASCA) and atypical pANCA (perinuclear antineutrophil cytoplasmic antibodies). [11] [12] [13] [14] [15] Other microbial antibodies found in IBD patients as antiOmpC (directed against the outermembrane porin C of Escherichia coli), I2 (antibodies directed against Pseudomonas fluorescens) and Cbir 1 (anti-flagellin antibodies) have not been studied in asymptomatic family members. [16] [17] [18] However, the presence of these subclinical markers has no clinical implications yet and longitudinal studies are needed first to evaluate their exact meaning.
Identification of susceptibility genes for IBD
Segregation studies have not supported a simple Mendelian model of inheritance for IBD. Instead, CD and UC are considered to be complex polygenic disorders. This means that several genes, together with environmental factors, contribute to the final clinical phenotype, which inevitably will be heterogeneous. How many susceptibility genes underlie IBD and how they interact with each other and with environmental factors is not precisely known, but the list of genes and environmental factors is growing each month. Since both forms of IBD can coexist in single families (and maybe also in the same individual?) with a frequency greater than expected by chance alone, CD and UC are likely to share some susceptibility genes. Orholm et al 3 showed that the crossdisease relative risks are 3.85 for UC, given a CD proband and 1.72 conversely, further suggesting the presence of shared genes among CD and UC. However, also disease-specific genes will exist since CD and UC are also very distinct in clinical features.
There are two main approaches to identify genes in complex multifactorial diseases: the positional cloning approach based on linkage studies and the candidategene approach based on association studies. Linkage analysis studies the cosegregation of the disease under study with a marker within families. The most used approach in the genetics of complex diseases is the method where allele sharing between affected sibling pairs is used. A distortion of the observed ratio of sharing vs the expected is taken as evidence for linkage with that particular marker. Linkage analysis allows scanning of the whole genome and has already been successfully undertaken in many complex diseases such as hypertension, schizophrenia, diabetes type I, asthma, rheumatoid arthritis, psoriasis, celiac disease, and also IBD.
Candidate gene analysis uses case-control cohorts or trios of affected offspring with both parents. Here, authors will investigate a specific gene, which has a known or potential interest for the disease under study. The allelic frequencies (in the case of case-control study) or the transmission of a single-nucleotide polymorphism (SNP) towards affected offspring (in the case of trios) will be studied and differences between patients and controls or an overtransmission towards affected children might point towards implication of this particular gene in the pathogenesis of the disease under investigation.
The human genome contains approximately 10 million SNPs and its genetic sequence is organized in haplotypes or stretches of DNA. SNPs that lie closely together ( ¼ on the same haplotype block) tend to be inherited together, whereas SNPs in different haplotype blocks are less likely to be inherited together. Recently, an International Haplotype Mapping (HapMap) Consortium was established to develop a HapMap of the genome, with the frequencies of common polymorphisms in the human genome in various populations in the world and with the extent of linkage disequilibrium (LD) between these polymorphisms and the haplotype blocks in which they fall. 19 This information is freely available on the internet (http://www.hapmap.org/). Therefore, instead of genotyping all SNPs in the genome, genotyping haplotypetagging SNPs (which are representative of a unique haplotype) will undoubtedly facilitate the identification of causal variants in complex diseases.
Also, technology has advanced greatly and the introduction of the so-called chip-arrays, containing up to 100 000 SNPs (with even larger chips being developed as we speak), has allowed high-throughput and highresolution genotyping of the whole genome. However, the high costs and also the informatics to analyse these huge amount of data are at this moment the bottle neck for wide-spread use of these techniques.
Results from linkage and candidate gene analyses in IBD
A total of 11 total genome-wide scans have been performed in IBD (Table 1) , resulting in a number of susceptibility regions on chromosomes 1, 3, 4, 5, 6, 7, 10, 12, 14, 16, 19 and X. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] According to their initial date of reporting, and independent confirmations, the regions on chromosomes 16, 12, 6, 14, 5, 19 and 1 have been renamed as IBD1-7, respectively. It must be stressed that no single locus has been reported in a constant manner through all genome scans, suggesting important genetic heterogeneity. Nevertheless, variation in phenotypes and lack of power also explain some of the discrepancies.
To search for IBD regions that are common for all populations, two meta-analyses have been performed. 27, 31 . The first by Williams et al included five genome scans [22] [23] [24] [26] [27] for which the complete results were published at that time. The highest evidence for linkage for IBD was obtained for the IBD3 locus, followed by the IBD1 and IBD2 locus. 27 Analysis of the CD-only families gave strongest results for IBD3, followed by IBD5, IBD1, IBD2, IBD6 and IBD7. The second meta-analysis by van [36] [37] [38] [39] [40] The protein consists of two N-terminal CARD, a central nucleotide-binding domain and a C-terminal leucin-rich-repeat region (LRR) ( Figure 1 ). CARD15 is involved in the recognition of bacterial peptidoglycanderived muramyl dipeptide (MDP) through the LRR region. 38, 41 Recognition of MDP will stimulate secretion of anti-microbial peptides including alpha-defensins (also called cryptdins) to protect the host from invasion. 42 A reduced expression of these defensins has been found in CD patients and this reduction is even more pronounced in patients with CARD15 mutation. 42, 43 However, the exact pathways through which signalling occurs are still unclear. The frameshift mutation 1007fsinsC, which leads to a truncated protein lacking the 33 distal amino acids, was associated with impaired activation of the transcription factor NF-kappa B (NF-kB) after stimulation in the initial paper by Ogura et al. 34 However, this is contradictory to the increased NF-kB activity observed in CD. In vivo studies using CARD15 À/À KO animals have also shown conflicting results, whereas Watanabe et al 44 showed that intact CARD15 signalling inhibits Toll-like receptor (TLR) 2-driven activation of NF-kB, and that the presence of a CARD15 mutation increased TLR 2-mediated activation of NF-kB; the study by Maeda et al 45 showed that CARD15 mutant mice had increased NF-kB activation directly in response to MDP.
Other susceptibility genes
In the last year, more genes have been reported using positional cloning techniques and fine mapping of identified susceptibility regions from total genome scans. The number of affected sibling pairs (asp) studied and the regions of linkage identified in each genome scan are indicated.
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So has the gene underlying the chromosome 10 linkage region, originally identified by Hampe et al, 23 been identified as DLG5 (for its homology with Drosophila Discs Large Homolog 5). In the study by Stoll et al, 46 two haplotypes were associated with IBD. One haplotype, characterized by the haplotype-tagging SNP G113A (leading to a change from arginine to glutamine at amino-acid position 30 (R30Q)), was overtransmitted to affected offspring with CD and UC. This SNP is located in the DUF622 domain and influences binding to RabGTPase, which is important in inflammatory signalling. In an independent case-control sample, 25% of IBD patients carried at least one 113A risk allele compared to 17% of healthy controls (P ¼ 0.001). The overall risk for IBD associated with the 113A variant was however moderate (odds ratio (OR) ¼ 1.6). The second haplotype, characterized by the presence of an insertion of 13 bp in exon 26 (DLG5_e26), was undertransmitted. DLG5 is a widely expressed protein, found in placenta, small bowel, colon, heart, skeletal muscle, liver and pancreas. It is a member of the MAGUK family (membraneassociated guanylate kinase) of scaffolding proteins important in signal transduction and epithelial cell integrity. The authors also examined gene-gene interactions between DLG5 and CARD15, and showed interaction between the 113A variant on haplotype D and the presence of CARD15 variants. Meanwhile, replication studies have emerged, but results are conflicting. Whereas Daly et al 47 was able to show independent replication in two cohorts from Quebec/ Italy and Quebec/UK, other recent studies were not able to show association. [48] [49] [50] More studies are inevitably needed to understand more about this gene.
At the same time last year and published in the same issue of Nature Genetics, Peltekova et al 51 identified the gene underlying the IBD5 locus as the SCL22A4 and SLC22A5 genes, coding for, respectively, the OCTN1 and 2 (novel organic cation transporter) proteins. It was Rioux et al 26 who first reported linkage for CD on 5q31 in the Canadian population. IBD5 is very attractive as a candidate region for IBD, since it harbours the cytokine gene cluster. Fine mapping of this locus refined the region to a 250 kb risk haplotype (surrounding the OCTNs), but precise identification of the underlying causal genetic variants was impossible due to strong LD across the region. 52 At least three independent groups subsequently confirmed association of the IBD5-risk haplotype with CD [53] [54] [55] [56] and also with UC. 53 , 55 Peltekova et al resequenced the five known genes in the IBD5 region and identified 10 new SNPs, including two novel SNPs in SLC22A4 and SLC22A5 that were predicted to have functional effects (a missense substitution in SLC22A4 (L503F) and a G-C transversion in the SLC22A5 promoter) and that were associated with susceptibility to CD. The OCTN family is a family of transporter proteins for organic cations, and may also transport carnitine, an essential cofactor of the metabolism of lipids. [57] [58] [59] [60] Carnitine is involved in the transport of long-chain fatty acids into the mitochondria, where fatty acids will undergo b-oxidation. Hence, carnitine is important in the energy production of the cell. There is evidence that inhibition of fatty acid oxidation in the epithelium of the colonic mucosa is associated with the development of UC. Rectal instillation of sodium 2-bromo-octanoate, a specific inhibitor of b-oxidation, produces weight loss and bloody diarrhoea in rats with histological signs of ulcers, mucus cell depletion, vessel dilatation and increase of acute inflammatory cells. 61 Peltekova et al 51 showed that fibroblasts expressing the 503F variant had a 2.7 times lower carnitine uptake and an increased transport of xenobiotics compared to the cells expressing the conservative 503L. The OCTN2 promoter variant disrupts a heat-shock element (HSE) 207 bp upstream of the start codon.
Recently, a strong association between a complex functional NOD1 (CARD4) insertion/deletion polymorphism (ND(1) þ 32 656*1) and IBD was found by investigators at the University of Oxford. 62 NOD1 has analogy to CARD15 and is located in the region of linkage on 7p14, identified in the original genome scan from the same group. 20 Intriguingly, this gene was examined previously by the French group lead by Hugot et al, but no association with this gene in CD patients was observed. 63 Again, independent studies are necessary before firm conclusions can be made.
From a candidate gene approach, the MHC region is the region studied most extensively. HLA class II molecules present partially digested antigen to the T-cell receptor and play a central role in the immune response. In contrast with other immune-mediated complex diseases such as rheumatoid arthritis, multiple sclerosis and IDDM, results on the role of the MHC complex in IBD are inconsistent, heterogeneous and often very weak. [64] [65] [66] [67] In Japanese studies, HLA DR2 (HLA DRB1*1502) has been implicated in UC, whereas HLA DR3 (HLA DRB1*0103) has been implicated in European studies. In CD, HLA associations are less convincing. HLA DR1 has been associated with the CD phenotype.
After the identification and knowledge of the function of CARD15, researchers have expressed major interest in the PRRs to which CARD15, and also the membraneexpressed TLRs belong. A Belgian collaborative study described an association between the TLR4 Asp299Gly polymorphism and IBD in two independent cohorts of patients. 68 This polymorphism is associated with impaired LPS signalling and increased susceptibility to Gram-negative infections. In the Belgian study, the allele frequency of the TLR4 Asp299Gly polymorphism was significantly higher in CD (11 vs 5%, OR 2.31 (95% confidence interval (CI) 1.28-4.17), P ¼ 0.004) and UC patients (10 vs 5%, OR 2.05 (95% CI 1.07-3.93), P ¼ 0.027) compared with the control population. A TDT on 318 IBD trios demonstrated preferential transmission of the TLR4 Asp299Gly polymorphism from heterozygous parents to affected children (T/U: 68/34, P ¼ 0.01). Replication studies performed in UC as well as CD have shown conflicting results so far.
69-72
Translation of IBD-genetic research into the clinic CARD15 variants are found in the majority of the Caucasian CD patients and vary between 35 and 45%, [73] [74] [75] [76] [77] [78] [79] [80] [81] with the exception of Scandinavian, 81 Irish 82 and Scottish 83 CD patients where the prevalence is much lower. In the Japanese 84, 85 and Chinese, 86 as well as in African-American populations, 87 no CARD15 variants could be identified. CARD15 explains around 20% of the genetic predisposition to CD. The relative risk of Current status of genetics research in IBD S Vermeire and P Rutgeerts developing CD in the presence of one mutation is 2-4, but increases dramatically to 20-40 in the case of two mutations (compound heterozygous or homozygous). Several studies have investigated the phenotypic expression of CARD15 variants and the most widely replicated association is seen with small bowel disease. 35, [73] [74] [76] [77] [78] [79] [80] [81] Patients with double-dose mutations in a French study were characterized by a more frequent structuring phenotype (53 vs 28%; P ¼ 0.00003 OR 2.92), 35 which has also been confirmed by others. 73, 78, 81, 88 Besides the implication of CARD15 mutations in CD, this gene seems implicated in graft-versus-host disease (GvHD) and complications following allogeneic stem cell transplantation. 89 In patients receiving stem cell transplantation, the transplant-related mortality in donor/ recipient pairs with mutations was much higher (49%) in contrast to the mortality in donor/recipient pairs without mutated CARD15 (20%). The mortality was even higher (83%) in pairs with mutated alleles in both donor and recipients (Po0.001). Similar associations have been observed for severe overall and severe gastrointestinal GvHD.
Very little is known so far about the clinical expression of the novel reported genes DLG5, OTCN, NOD1 or TLR4. For IBD5 and OCTN1 and 2, results have not been consistent so far and associations with perianal disease, 50, 90, 91 with ileal disease 92 as well as with colonic disease, with an earlier age of disease onset and reduced need for surgery 49 have all been reported. Large studies with phenotypically well-characterized patients are therefore greatly needed.
Also, the HLA system influences the disease phenotype. Genetic markers in the MHC, especially the class II HLA DRB1*0103 allele, have been associated with severe cortico-dependent and refractory UC as well as severe UC necessitating colectomy. 66, 93 It is well possible that the HLA gene plays a disease-modifying role, rather than being an important gene in the susceptibility for developing IBD: a UK study found that certain HLA alleles are associated with different disease behaviour and extraintestinal manifestations such as IBD-arthropathy, as well as eye and skin manifestations. 94, 95 The HLA-B27 and -B35 were associated in this study with the large joint type of IBD-arthropathy, whereas HLA-B44 was increased in the small joint type of IBD-arthropathy.
94-96
The emerging field of pharmacogenetics in IBD Genes interfere with the metabolizing pathways of drugs and may influence the clinical response and the drugrelated toxicity. With increasing knowledge of the variations within the human genome sequence, researchers and clinicians aim at personalizing medicine and at optimizing a patient's treatment based on his/her genotype.
Interesting results have been generated to predict the answer to steroid treatment in IBD. One mechanism of action is related to the multidrug resistance gene MDR-1. MDR-1 encodes the drug efflux pump P-glycoprotein 170 (Pgp-170). Various polymorphisms have been identified within MDR-1: a mutation C3435T in exon 26 and a mutation G2677T in exon 21 have been correlated with altered Pgp expression and function in humans. 97 Overexpression of MDR-1 leads to an increased efflux of drugs and to decreased cytoplasmic drug concentrations. Several drugs, including glucocorticoids, are known Pgp-170 substrates. Farrell et al 98 showed that, compared to controls, peripheral blood lymphocyte (PBL) MDR was significantly elevated in CD patients who required bowel resection for failed medical therapy (mean7s.e.m. 26.772.8 vs 11.971.0; Po0.0001). Also, patients with UC who required proctocolectomy for failed medical therapy had elevated PBL MDR compared to controls (mean7s.e.m. 20.372.5 vs 11.971.0; Po0.0001). A second mechanism responsible for the glucocorticoid resistance lies at the level of the glucocorticoid receptor (GR) and polymorphisms in the gene encoding this receptor (GRb) influence the response to corticosteroid treatment in IBD. Overexpression of GRb is associated with steroid-refractory UC, in contrast to steroid-responsive UC. 99 Of all drugs used in IBD, azathioprine (AZA) is the only drug where pharmacogenetics have shown clinical relevance to date. AZA is one of the best examples of genetically influenced heterogeneity in drug response. The pathway of AZA metabolism is illustrated in Figure 2 . In a first step, AZA is converted by a nonenzymatic reaction into 6-mercaptopurin (6-MP). Subsequently, 6-MP is metabolized by competing catabolic and anabolic enzymatic pathways: xanthine oxidase converts 6-MP into the inactive 6-thiouric acid (6-TU). Alternatively, 6-MP may be methylated to 6-methyl MP (6-MMP) by the enzyme thiopurine methyl transferase (TPMT). A third pathway is metabolization towards active 6 thioguanine (6-TG) nucleotides, which are incorporated as false bases into the DNA and would explain the cytotoxicity of the drug. The activity of TPMT is genetically regulated. 100, 101 In the Caucasian population, TPMT*3A and TPMT*3C are the most common variant alleles. Approximately 11% of the population is heterozygous for the common TPMT polymorphisms and around 1/300 is homozygous mutant. Heterozygous patients show decreased activity of TPMT and patients homozygous have almost absent TPMT activity. A deficiency of TPMT results in a preferential production of 6-TG nucleotides, which in its turn explains the risk of bone marrow suppression and neutropenia. 102, 103 However, Colombel et al 104 genotyped 41 patients who previously demonstrated signs of bone marrow toxicity (leucopenia or thrombocytopenia) upon AZA treatment and showed only 65.8% (27/41) of TPMT mutations in these patients (10 were homozygous and 17 heterozygous). The duration of onset of the bone marrow suppression was significantly shorter in the homozygous patients (o1.5 months) compared to the wild-type patients (0.5-87 months) and the heterozygous patients had an onset in between that of wild-type and of homozygous patients (1-18 months). However, these results suggest that also other factors are responsible for bone marrow suppression. Besides bone marrow suppression, hepatotoxicity is a second adverse event of AZA metabolism and would be related to 6-MMP. Dubinsky et al 105 showed that the 16/173 CD patients with hepatotoxicity had high MMP levels (median 5463) compared to patients without those symptoms (median MMP 2213; Po0.05). A cutoff of MMP45700 pmol/ 8 Â 10
8 RBC was associated with hepatotoxicity. Remark-ably also was the fact that none of the patients with hepatotoxicity carried genetic variants in the TPMT gene. These data suggested that certain patients preferentially metabolize through TPMT, resulting not only in higher 6-MMP levels and more risk of hepatotoxicity but also in lower 6-TG levels.
Other side effects of AZA as pancreatitis, fever, myalgias and arthralgias are type I hypersensitivity reactions and should not lead to genetic testing. In these patients, AZA should be stopped and rechallenge is not recommended.
Also for the novel biological treatment infliximab, a chimeric monoclonal antibody to TNFa approved for the treatment of active luminal and fistulizing CD, genetic factors have been investigated to explain the lack of response seen in 25% of patients. Various polymorphisms in the TNFa and b genes and in their receptors have been examined but failed to show clear associations. [106] [107] [108] Following the discovery of NOD2/CARD15, it was postulated that mutations in NOD2/CARD15 might predict therapy outcome based on changes in NF-kB activation and subsequent TNF production. However, three independent cohorts of patients treated with infliximab (one Belgian n ¼ 245; one German n ¼ 90 and the ACCENT I Cohort n ¼ 444) failed to show an association. 109, 110 In a Belgian collaborative study, an association with FCGR3A-158 was described. 111 The FcG recptor 3a is expressed on macrophages and NK cells and is involved in ADCC. In the study by Louis et al in 200 patients treated with infliximab, all patients with the V/V genotype showed biological response compared to 69.8% of patients carrying the F allele (P ¼ 0.0002; RR 1.43, 95% CI 1.27-1.61). Interestingly, the FCGR3A polymorphism has also been associated with a positive response to rituximab, a recombinant IgG1 antibody used in non-Hodgkin's lymphoma. 112, 113 The effect of infliximab is ascribed to induction of apoptosis. In a cohort of 204 consecutive patients treated with infliximab for refractory luminal CD, Hlavaty et al 114 
Conclusion
The recent advances in the research on genetic susceptibility of IBD have been tremendous. Total genome scans have generated over 10 regions of linkage, which are in the process of fine mapping. These efforts have already led to the identification of a number of susceptibility genes (CARD15, DLG5, OCTN1 and 2, NOD1, HLA, TLR4), of which the CARD15 gene is undoubtedly replicated most widely and most understood at present. However, even for the CARD15 gene, a number of questions remain especially concerning the mechanisms of signalling. Answers to these questions will further improve our knowledge on the pathogenesis of the disease in the common years. Genetic research in IBD has advanced our understanding of the clinical heterogeneity of the disease and has started to tackle the complex interactions between genetic risk factors and environmental risk factors in IBD. It is anticipated that these discoveries in the future will be translated back into clinical practise where genetic markers will find their place in an integrated molecular diagnostic and prognostic approach of our patients. Figure 2 Azathioprine metabolism. In a first step, azathioprine is rapidly converted by a nonenzymatic reaction into 6-mercaptopurin (6-MP). Subsequently, 6-MP is metabolized by competing catabolic and anabolic enzymatic pathways: xanthine oxidase (XO) converts 6-MP into the inactive 6-thiouric acid (6-TU). Alternatively, 6-MP may be methylated to 6-methyl MP (6-MMP) by the enzyme thiopurine methyl transferase (TPMT). The active 6 thioguanine nucleotides (6-TGNs) are generated in a multistep pathway, which is initiated by hypoxanthine guanine phosphoribosyl transferase (HGPRT).
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